Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab

:  Multicentric Castleman's disease (MCD) is an indolent lymphoproliferative disorder. The pathogenesis of MCD has not been established, and its treatment remains uncertain. Several authors have described the relationship of human herpes virus type 8 (HHV‐8) to MCD in human immunodeficiency vir...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2006-02, Vol.76 (2), p.119-123
Main Authors: Ide, Makoto, Kawachi, Yasunori, Izumi, Yoichiro, Kasagi, Kanji, Ogino, Tetsuro
Format: Article
Language:English
Subjects:
Adult
anti-CD20 monoclonal antibody
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Castleman Disease - drug therapy
Castleman's disease
Female
Herpesvirus
HIV Seronegativity
HIV-negative patients
Human herpesvirus 8
Human immunodeficiency virus
Humans
Immunologic Factors - therapeutic use
Male
Middle Aged
Polymerase Chain Reaction
Remission Induction
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary::  Multicentric Castleman's disease (MCD) is an indolent lymphoproliferative disorder. The pathogenesis of MCD has not been established, and its treatment remains uncertain. Several authors have described the relationship of human herpes virus type 8 (HHV‐8) to MCD in human immunodeficiency virus (HIV)‐positive patients. Recently, anti‐CD20 monoclonal antibody (rituximab) is increasingly being used to treat HIV‐positive MCD; although it is uncertain whether rituximab is effective for HIV‐negative patients with MCD. To explore the benefit of rituximab for HIV‐negative patients with MCD, we describe the clinical and biologic course in three HIV‐negative patients with MCD, and examined the relationship of HHV‐8 infection to HIV‐negative MCD. Their polymerase chain reaction analyses for the HHV‐8 sequence in peripheral blood were negative, and there was no relationship between HHV‐8 infection and symptoms of HIV‐negative MCD. Two of three patients (66%) achieved a near complete remission with no clinical symptoms due to MCD with a follow‐up of 16–40 months after rituximab administration. One of the three patients presented no clinical remission of MCD after rituximab administration, although a significant decrease of inflammatory parameters was observed. These findings suggest that rituximab treatment may be an appropriate first‐line therapy for HIV‐negative MCD.
ISSN:0902-4441
1600-0609
DOI:10.1111/j.1600-0609.2005.00570.x